Bausch Health Companies Inc faced a notable decline in its stock value during yesterday's trading session.
The stock of Bausch Health Companies Inc (BHC.TO) fell by 3.48% yesterday, closing at CA$6.38. This drop comes amidst a lack of significant news that could have influenced investor sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.47B
52W high
$11.97
52W low
$6.10
1W change
-4.63%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 9.9% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+9.9% Upside
Current Price
C$6.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
45.2%
Annualized
90-Day Vol
41.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.34
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$6.01 | C$5.14 โ C$7.03 |
| 60 trading days | C$5.66 | C$4.54 โ C$7.06 |
| 90 trading days | C$5.34 | C$4.07 โ C$6.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Bausch Health continues to navigate a challenging market environment without clear catalysts for growth.
Bausch Health's stock down 3.48% yesterday
The decline marks a concerning trend as the company struggles with profitability, evidenced by a profit margin of -11.47%.
Bull case
If Bausch Health can successfully execute its upcoming financial strategies, particularly with its Q1 2026 results expected soon, it may regain investor confidence. Positive outcomes from these strategies could signal a turnaround and attract more investors.
Bear case
Continued losses and a lack of positive news could further erode investor trust, especially given the company's recent performance metrics. Without clear signs of improvement, investors may remain skeptical about the company's future prospects.
Market Reaction
The 3.48% drop in Bausch Health's stock price reflects a broader uncertainty in the pharmaceutical sector. Investors appeared to react to the lack of recent positive developments, leading to a sell-off that could suggest a lack of confidence in the company's near-term prospects.
Financial Performance Context
With a market cap of approximately CA$2.46 billion and a troubling profit margin of -11.47%, Bausch Health's financial health is under scrutiny. The absence of dividends and the P/E ratio being not applicable further complicate the investment landscape for potential buyers.
Looking Ahead
As Bausch Health prepares to announce its first quarter results for 2026, stakeholders will be keenly watching for any signs of recovery or strategic shifts that could impact stock performance. The upcoming release could serve as a pivotal moment for the company.
Advertisement
